ProCE Banner Activity

Ibrutinib Plus Rituximab and the Expanding Therapeutic Toolbox for Previously Untreated CLL

Clinical Thought
With the recent approval of ibrutinib plus rituximab for the frontline treatment of CLL, how should therapeutic choices be made in an increasingly complex landscape? Here’s my approach.

Released: June 26, 2020

Expiration: June 25, 2021

Share

Faculty

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by the USF Health
ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, has disclosed that he has received consulting fees from AbbVie, Adaptive, AstraZeneca, Celgene, Genentech, Johnson & Johnson, Loxo, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics and funds for research support from AbbVie, Adaptive, Acerta, DTRM, Genentech, Johnson & Johnson, Loxo, Pharmacyclics, Portola, Regeneron, Sunesis, and TG Therapeutics.